Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-oHCM: Tapering and Discontinuation of Beta-blockers in oHCM Patients on Mavacamten
NCT07815301Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of carvedilol in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Clinical and Hemodynamic Strategy Success Rate at 24 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07815301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815301.